1-3 of 3
Peter Ordentlich, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of Axatilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment

Mukta Arora, MD, Madan Jagasia, MBBS, MS, MMHC, Antonio Di Stasi, MD, Michael L Meyers, MD PhD, Christine Quaranto, Aaron Schmitt, Serap Sankoh, Mohammad Issam Abu Zaid, MBBS, Geoff R Hill, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Peter Ordentlich, PhD, Stephanie J. Lee, MDMPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-141553
Published: 2020
Journal Articles

A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia

Hetty E Carraway, MD, MBA, Judith E. Karp, MD, Ivana Gojo, MD, Keith W. Pratz, MD, Nilanjan Ghosh, MD, PhD, Steven D. Gore, MD, Margaret M. Showel, MD, Mark Levis, MD, PhD, B. Douglas Smith, Jacqueline Greer, James G. Herman, MD, Lia Gore, MD, Min-Jung Lee, PhD, Sunmin Lee, PhD, Peter Ordentlich, PhD, Richard Piekarz, MD, PhD, Jane Trepel, PhD
Journal: Blood
Blood (2013) 122 (21): 1427.
https://doi.org/10.1182/blood.V122.21.1427.1427
Published: 2013
Journal Articles

Alkylator-Induced DNA Damage Response in Multiple Myeloma (MM) Cells Is Amplified by Histone Deacetylase (HDAC) Inhibition, Resulting in Significant Synergism in Cell Death

Choon Kee Lee, MD, Shuiliang Wang, M.D., Xiaoping Huang, M.D., John Ryder, M.D., Peter Ordentlich, PhD, Bolin Liu, M.D.
Journal: Blood
Blood (2008) 112 (11): 5157.
https://doi.org/10.1182/blood.V112.11.5157.5157
Published: 2008